Drug Profile
BMS 986277
Alternative Names: BMS-986277Latest Information Update: 01 Jan 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cancer
Most Recent Events
- 19 Dec 2020 Bristol-Myers Squibb terminates phase I/II clinical trials in Cancer (Monotherapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therap) in Canada and USA (unspecified route), as the company's business objectives have changed (NCT03363776)
- 07 Jan 2020 Phase-I/II development is ongoing in USA and Canada